 TRACON Pharmaceuticals Inc has received a recommendation from the Independent Data Monitoring Committee that its ENVASARC Phase 2 pivotal trial can proceed as planned, the company announced. The committee made its recommendation following a review of 12-week safety data from patients enrolled in the trial as of June 30. 